Table 1.

Recent randomized trials of chemotherapy in the treatment of advanced Hodgkin lymphoma.

RegimenNo. of patientsCR, %FFS, %OS, %Heme toxicity grade 3–4, %RAD,* %
*Patients receiving radiotherapy on protocol 
**Statistically significant 
Chemotherapy regimens: As referenced in article, escBEACOPP, escalated BEACOPP4; Modified Stanford V as by Gobbi et al; MDR, either ChlVPP/PABIOE (alternating) of CHlVPP/ EVA (hybrid)9; CEC, COPPEBVCAD.8  
NS indicates not stated 
MOPP/ABV 419 80 66 (5 y) 82 74.6 0 
ABVD66  433 76 63 81 63.6** 0 
COPP/ABVD 260 85 69 (5 y) 83 71 64 
BEACOPP 469 88 76 88 73 71 
EscBEACOPP4  466 96 87 91** 98** 71 
Mod Stanford V 107 76 54 (5 y) 82 29 66 
MOPPEBVCAD 106 94 81 89 51** 47 
ABVD10  122 89 78 90 21 62 
Stanford V 259 ns 76 (5 y) 92 NS 53 
ABVD12  261 NS 74 90 56 38 
MDR 394 67 75 (3 y) 88 (3 y) 65** 40 
ABVD9  394 68 75 90 56 38 
BEACOPP 102 91 81 (5 y)** 92 (5 y) 54 44 
CEC 102 83 78 91 48 43 
ABVD8  103 84 68 84 34** 46 
RegimenNo. of patientsCR, %FFS, %OS, %Heme toxicity grade 3–4, %RAD,* %
*Patients receiving radiotherapy on protocol 
**Statistically significant 
Chemotherapy regimens: As referenced in article, escBEACOPP, escalated BEACOPP4; Modified Stanford V as by Gobbi et al; MDR, either ChlVPP/PABIOE (alternating) of CHlVPP/ EVA (hybrid)9; CEC, COPPEBVCAD.8  
NS indicates not stated 
MOPP/ABV 419 80 66 (5 y) 82 74.6 0 
ABVD66  433 76 63 81 63.6** 0 
COPP/ABVD 260 85 69 (5 y) 83 71 64 
BEACOPP 469 88 76 88 73 71 
EscBEACOPP4  466 96 87 91** 98** 71 
Mod Stanford V 107 76 54 (5 y) 82 29 66 
MOPPEBVCAD 106 94 81 89 51** 47 
ABVD10  122 89 78 90 21 62 
Stanford V 259 ns 76 (5 y) 92 NS 53 
ABVD12  261 NS 74 90 56 38 
MDR 394 67 75 (3 y) 88 (3 y) 65** 40 
ABVD9  394 68 75 90 56 38 
BEACOPP 102 91 81 (5 y)** 92 (5 y) 54 44 
CEC 102 83 78 91 48 43 
ABVD8  103 84 68 84 34** 46 
View Large